Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Terumo Heart, Inc. Reaches Clinical Milestone As The 100th Patient Worldwide Receives The DuraHeart(TM) Left Ventricular Assist System
Terumo Heart Inc., a wholly owned subsidiary of Terumo Corporation, announced reaching a critical milestone in the worldwide expansion of its DuraHeart(TM) Left-Ventricular Assist System (LVAS) as the 100th patient was treated by Latif Arusoglu, MD and Michiel Morshuis, MD, cardiothoracic surgeons at the Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, University Hospital of the Ruhr-University of Bochum in Bad Oeynhausen, Germany.
generic viagra online
Eversheds Comment: NHS Told To Tighten Data Security
Following calls from the information commissioner for the NHS to improve its data security, after breaches involving the loss of thousands of personal medical records, Bill Gilliam, head of the health sector group at international law firm Eversheds comments:
News of the day
FDA Approves Expanded Use Of Lilly's FORTEO(R) [teriparatide (rDNA Origin) Injection] To Treat Glucocorticoid-Induced Osteoporosis
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO((R)) [teriparatide (rDNA origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture. Glucocorticoid therapy is the most common cause of secondary osteoporosis, leading to bone loss and an increased risk for fracture.(1)
Sexual Health

InVitria To Unveil Powerful Cell Culture Media Component ZAP-CHO

InVitria"s Director of Cell Culture, Dr. Steve Pettit, will present the performance enhancing features of ZAP-CHO, a new media component for Chinese hamster ovary (CHO) cell culture, at 3:30 pm on Wednesday, May 20, 2009 as part of BioProcess International"s BioProcess Theatre, a venue employed to facilitate the sharing of advances and discoveries in the biopharmaceutical sector. ZAP-CHO, a new product from InVitria , enhances performance of mammalian cell culture including improved cell growth and antibody production. It achieves these performance advantages in chemically defined media that are completely free of animal components. Previously, the performance seen with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum), BSA (bovine serum albumin) or plasma-derived HSA (human serum albumin) in cell culture media. "Our team of scientists has developed supplements that not only meet the regulatory requirements of researchers using hybridoma and CHO cell culture, but it exceeds their performance expectations as well," said Dr. Pettit. "InVitria products have been utilized by customers to successfully achieve greater cell productivity and growth; faster cell doublings; and improved consistency." InVitria"s other leading cell culture media supplements will also be part of the BIO Process Product Zone exhibition in Booth #5120 within the BIO 2009 International Convention from May 19-21. These supplements include: * Albumin-DX -whether you have problems with non-specific binding, biomarker stability, consistency or regulatory requirements, Albumin-DX was designed to answer the most difficult assay challenges. * Cellastim -Cellastim outperforms plasma-derived albumin, bovine serum albumin and other s of recombinant albumin. * Lacromin -Lacromin is a CHO growth-factor that outperforms insulin and IGF-1. InVitria


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009